Antibody and T-cell responses to NY-ESO-1 43, high baseline expression of immune markers such as FoxP3 and indoleamine 2,3-dioxygenase 44, increases in tumor-infiltrating lymphocytes, and changes in expression of immune-related genes 44 have all been correlated with clinical activity or benefit of ipilimumab. Here, FOXP3 is linked to neoplasm.